<DOC>
	<DOCNO>NCT00171574</DOCNO>
	<brief_summary>Title : Antiproteinuric effect valsartan , lisinopril valsartan versus lisinopril non-diabetic diabetic renal disease : randomize ( 3:3:1 ) , double blind , parallel group , control trial , 5 month follow-up . Objective : To evaluate antiproteinuric effect high dos valsartan vs combo treatment no-diabetic diabetic patient . Hypothesis : Combo treatment reduces microalbuminuria , proteinuria albumin/creatinin ratio monotherapies . Design : Multicentric , randomize , double blind , parallel group , active control . Dose / regimen Valsartan 320 v Lisinopril 40 v Valsartan/lisinopril 160/20</brief_summary>
	<brief_title>Antiproteinuric Effect Valsartan Lisinopril</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Male female outpatient age 1870 year , 2 . Chronic nephropathy , define serum creatinine concentration &gt; 3 mg/dL calculate glomerular filtration rate &gt; 30 mL/min/1.73 m2 . 3 . Persistent proteinuria , define urinary protein excretion exceed 1g/24 h. ( minimum three month ) . 4 . Normotensive hypertensive patient adequately control without treatment ( control : &lt; 125/75 mmHg ) . 5 . Written inform consent participate study prior study procedure . Exclusion Criteria Immediate need renal replacement therapy . Treatment resistant oedema . Need treatment corticosteroid , nonsteroidal antiinflammatory drug , immunosuppressive drug . Proteinuria great 10g /24h and/or hypoalbuminaemia less 28g/L . Renovascular hypertension Malignant hypertension MI , cerebrovascular accident within last year , severe peripheral vascular disease , CHF , chronic hepatic disease . Angiotensin convert enzyme inhibitor angiotensin II receptor blocker within one month prior randomization . A serum creatinine concentration &gt; 265 Ã¼mol/L Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>valsartan</keyword>
	<keyword>lisinopril</keyword>
	<keyword>antiproteinuric</keyword>
	<keyword>diabetic nephropathy</keyword>
</DOC>